Department of Microbiology and Immunology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
J Virol. 2012 Nov;86(21):11533-40. doi: 10.1128/JVI.00615-12. Epub 2012 Aug 15.
A major goal in rabies virus (RV) research is to develop a single-dose postexposure prophylaxis (PEP) that would simplify vaccination protocols, reduce costs associated with rabies prevention in humans, and save lives. Live replication-deficient RV-based vaccines are emerging as promising single-dose vaccines to replace currently licensed inactivated RV-based vaccines. Nonetheless, little is known about how effective B cells develop in response to live RV-based vaccination. Understanding this fundamental property of rabies immunology may help in developing a single-dose RV vaccine. Typically, vaccines induce B cells secreting high-affinity, class-switched antibodies during germinal center (GC) reactions; however, there is a lag time between vaccination and the generation of GC B cells. In this report, we show that RV-specific antibodies are detected in mice immunized with live but not inactivated RV-based vaccines before B cells displaying a GC B cell phenotype (B220(+)GL7(hi)CD95(hi)) are formed, indicating a potential role for T cell-independent and early extrafollicular T cell-dependent antibody responses in the protection against RV infection. Using two mouse models of CD4(+) T cell deficiency, we show that B cells secreting virus-neutralizing antibodies (VNAs) are induced via T cell-independent mechanisms within 4 days postimmunization with a replication-deficient RV-based vaccine. Importantly, mice that are completely devoid of T cells (B6.129P2-Tcrβ(tm1Mom) Tcrδ(tm1Mom)/J) show protection against pathogenic challenge shortly after immunization with a live replication-deficient RV-based vaccine. We show that vaccines that can exploit early pathways of B cell activation and development may hold the key for the development of a single-dose RV vaccine wherein the rapid induction of VNA is critical.
狂犬病病毒(RV)研究的一个主要目标是开发单剂量的暴露后预防(PEP),这将简化疫苗接种方案,降低人类狂犬病预防相关成本,并拯救生命。基于活复制缺陷 RV 的疫苗作为有前途的单剂量疫苗正在出现,以取代目前许可的基于灭活 RV 的疫苗。尽管如此,对于活 RV 疫苗接种如何有效地诱导 B 细胞,人们知之甚少。了解狂犬病免疫学的这一基本特性可能有助于开发单剂量 RV 疫苗。通常,疫苗在生发中心(GC)反应中诱导分泌高亲和力、类别转换抗体的 B 细胞;然而,在接种疫苗和产生 GC B 细胞之间存在时间延迟。在本报告中,我们表明,在形成显示 GC B 细胞表型(B220(+)GL7(hi)CD95(hi))的 B 细胞之前,用活 RV 基疫苗而非灭活 RV 基疫苗免疫的小鼠中可检测到 RV 特异性抗体,表明在 RV 感染保护中,T 细胞非依赖性和早期滤泡外 T 细胞依赖性抗体反应可能发挥作用。使用两种 CD4(+)T 细胞缺陷小鼠模型,我们表明,通过 T 细胞非依赖性机制,在接种复制缺陷 RV 基疫苗后 4 天内诱导分泌病毒中和抗体(VNAs)的 B 细胞。重要的是,完全缺乏 T 细胞的小鼠(B6.129P2-Tcrβ(tm1Mom) Tcrδ(tm1Mom)/J)在接种活复制缺陷 RV 基疫苗后不久即可免受致病性挑战的保护。我们表明,能够利用 B 细胞激活和发育早期途径的疫苗可能是开发单剂量 RV 疫苗的关键,其中快速诱导 VNA 至关重要。